Neuropharmacology of Abused Stimulants in Nonhuman Primates
非人类灵长类动物滥用兴奋剂的神经药理学
基本信息
- 批准号:9094694
- 负责人:
- 金额:$ 12.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-06-01 至 2017-05-31
- 项目状态:已结题
- 来源:
- 关键词:AbstinenceAgonistAnimal ModelAreaAttenuatedAwardBehaviorBehavioralBehavioral ParadigmBlood VesselsBrainCocaineCollaborationsComplementCuesDataDetectionDevelopmentDopamineDoseDrug AddictionDrug usageEducational ActivitiesEffectivenessExhibitsExtinction (Psychology)FacultyFutureGoalsHealthIntakeInterventionInvestigationKnowledgeMagnetic Resonance ImagingMentorsMentorshipModelingMonkeysN-MethylaspartateNeuropharmacologyPathologyPharmaceutical PreparationsPositron-Emission TomographyPostdoctoral FellowProspective StudiesProtocols documentationPsychostimulant dependenceRegulationResearchResearch PersonnelRestRoleScientistSelf AdministrationSenior ScientistSerotonergic SystemSerotoninSocial BehaviorSubstance abuse problemTechniquesTrainingUniversitiesaddictionattenuationbehavioral pharmacologybrain metabolismcareercareer developmentcocaine usedrug abstinencedrug relapseeffective therapygraduate studentin vivoinhibitor/antagonistinsightinstructorinterestmonoamineneurobiological mechanismneurochemistryneuroimagingnonhuman primatenovelnovel markerpreventprofessorreceptorresearch studyskillsstimulant abusetherapeutic targettranslational study
项目摘要
DESCRIPTION (provided by applicant): The career development and mentorship plan described in this application will allow the applicant to continue the development and expansion of his research career into new areas of investigation that complement current areas of expertise. Specifically, I will have the opportunity to acquire new skills and expertise with MRI i functional connectivity and vascular pathology. I will collaborate with Dr. Mark Goodman on the development of novel biomarkers for PET in order to expand neuropharmacological targets beyond monoamine transporters. I also will initiate self-administration and PET neuroimaging studies at the Yerkes Field Station in order to focus on ethologically-relevant models of social behavior and drug use through collaboration with Dr. Mark Wilson. I plan to commit 75% effort during the five-year period of support in order to continue to advance my career in substance abuse research and enhance my role as a mentor. Approximately 50% effort will be devoted to the conduct of experiments once all research protocols are standardized. The proposed prospective studies in nonhuman primates will document the relevant neurochemical and functional changes that occur during cocaine use and apply this knowledge to evaluate the effectiveness of extinction therapy augmented with pharmacological intervention in normalizing brain function and preventing reinstatement as an animal model of drug relapse. These data will provide insights on pharmacological targets for future medications development, thus accelerating the discovery of effective treatments. Related studies will provide information concerning the basic role of serotonin in the regulation of dopaminergic function as it relates to the neuropharmacology of cocaine. These translational studies in nonhuman primates will determine the effectiveness of the serotonin system to modulate the abuse-related behavioral and neurochemical effects cocaine. Collectively, the integration of behavioral pharmacology, in vivo neurochemistry and functional neuroimaging will enhance our understanding of the neurobiological mechanisms involved in cocaine self- administration and reinstatement in nonhuman primates. Another 25% effort will be committed to mentoring of new, independent investigators. I plan to serve as the primary mentor of two junior faculty and as a secondary mentor for two additional faculty at the rank of Instructor or Assistant Professor. Through mentoring young scientists with broad areas of expertise, I will expand the breadth of techniques and general approaches applied to drug addiction research. The remaining 25% effort not supported by the Senior Scientist Research and Mentorship Award will be committed to University administrative responsibilities, other research-related pursuits consistent with the objectives of the award, including oversight of graduate students and postdoctoral fellows, and educational activities. The long-term commitment and support provided by a Senior Scientist Research and Mentorship Award will allow the implementation of these integrated techniques to novel research applications, and provide effective mentorship for new, independent investigators with an interest in drug addiction.
描述(由申请人提供):本申请中描述的职业发展和导师计划将使申请人能够继续发展和扩展他的研究生涯,进入新的调查领域,以补充当前的专业领域。具体来说,我将有机会获得MRI i功能连接和血管病理学方面的新技能和专业知识。我将与Mark Goodman博士合作开发PET的新型生物标志物,以扩大单胺转运体以外的神经药理学靶点。我还将在Yerkes野外站启动自我管理和PET神经成像研究,以便通过与Mark Wilson博士的合作,专注于社会行为和药物使用的行为学相关模型。我计划在五年的支持期间投入75%的努力,以继续推进我在药物滥用研究方面的职业生涯,并加强我作为导师的作用。一旦所有研究方案标准化,大约50%的努力将用于实验的进行。拟在非人灵长类动物中进行的前瞻性研究将记录可卡因使用期间发生的相关神经化学和功能变化,并将这些知识应用于评估药物干预增强的消退治疗在恢复脑功能和预防复发方面的有效性,作为药物复发的动物模型。这些数据将为未来的药物开发提供药理学靶点的见解,从而加速发现有效的治疗方法。相关研究将提供有关血清素在调节多巴胺能功能中的基本作用的信息,因为它与可卡因的神经药理学有关。这些在非人类灵长类动物中的转化研究将确定5-羟色胺系统调节可卡因滥用相关行为和神经化学作用的有效性。总的来说,行为药理学、体内神经化学和功能性神经成像的整合将增强我们对非人灵长类动物中可卡因自我给药和恢复所涉及的神经生物学机制的理解。另外25%的努力将致力于指导新的独立调查人员。我计划担任两个初级教师的主要导师,并作为二级导师的两个额外的教师在讲师或助理教授的职级。通过指导具有广泛专业领域的年轻科学家,我将扩大适用于药物成瘾研究的技术和一般方法的广度。其余25%的努力不支持高级科学家研究和导师奖将致力于大学的行政责任,其他研究相关的追求与奖励的目标一致,包括研究生和博士后研究员的监督,和教育活动。高级科学家研究和导师奖提供的长期承诺和支持将允许将这些综合技术应用于新的研究应用,并为对药物成瘾感兴趣的新的独立调查人员提供有效的导师。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effects of ketamine treatment on cocaine-induced reinstatement and disruption of functional connectivity in unanesthetized rhesus monkeys.
氯胺酮治疗对可卡因诱导的未麻醉恒河猴功能连接恢复和破坏的影响。
- DOI:10.1007/s00213-019-05204-4
- 发表时间:2019
- 期刊:
- 影响因子:3.4
- 作者:Maltbie,EricA;Gopinath,KaundinyaS;Howell,LeonardL
- 通讯作者:Howell,LeonardL
3,4-Methylenedioxymethamphetamine facilitates fear extinction learning.
- DOI:10.1038/tp.2015.138
- 发表时间:2015-09-15
- 期刊:
- 影响因子:6.8
- 作者:Young MB;Andero R;Ressler KJ;Howell LL
- 通讯作者:Howell LL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LEONARD L HOWELL其他文献
LEONARD L HOWELL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LEONARD L HOWELL', 18)}}的其他基金
Early life stress and adolescent cocaine abuse: neurobiological vulnerabilities
早期生活压力和青少年可卡因滥用:神经生物学脆弱性
- 批准号:
8794163 - 财政年份:2014
- 资助金额:
$ 12.37万 - 项目类别:
Early life stress and adolescent cocaine abuse: neurobiological vulnerabilities
早期生活压力和青少年可卡因滥用:神经生物学脆弱性
- 批准号:
8936366 - 财政年份:2014
- 资助金额:
$ 12.37万 - 项目类别:
Neuropharmacology of Abused Stimulants in Nonhuman Primates
非人类灵长类动物滥用兴奋剂的神经药理学
- 批准号:
8663206 - 财政年份:2012
- 资助金额:
$ 12.37万 - 项目类别:
Neuropharmacology of Abused Stimulants in Nonhuman Primates
非人类灵长类动物滥用兴奋剂的神经药理学
- 批准号:
8903700 - 财政年份:2012
- 资助金额:
$ 12.37万 - 项目类别:
Neuropharmacology of Abused Stimulants in Nonhuman Primates
非人类灵长类动物滥用兴奋剂的神经药理学
- 批准号:
8475570 - 财政年份:2012
- 资助金额:
$ 12.37万 - 项目类别:
Vulnerability biomarkers for cocaine abuse and relapse
可卡因滥用和复发的脆弱性生物标志物
- 批准号:
8495966 - 财政年份:2012
- 资助金额:
$ 12.37万 - 项目类别:
Neuropharmacology of Abused Stimulants in Nonhuman Primates
非人类灵长类动物滥用兴奋剂的神经药理学
- 批准号:
8241468 - 财政年份:2012
- 资助金额:
$ 12.37万 - 项目类别:
FUNCTIONAL BRAIN ACTIVITY AFTER COCAINE USE & EXTINCTION THERAPY IN NHP
使用可卡因后的大脑功能活动
- 批准号:
8357568 - 财政年份:2011
- 资助金额:
$ 12.37万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 12.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 12.37万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 12.37万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 12.37万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 12.37万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 12.37万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 12.37万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 12.37万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 12.37万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 12.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




